SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

PMVP

PMV Pharmaceuticals, Inc.
NASDAQHealth Care

Latest close: 1.21 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Oct 5, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Sep 2, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Aug 31, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record36917 flagged findings
Reported transactions (Form 4)62since Nov 25, 2022 · and 11 other holdings
Corporate events (8-K)9since Apr 6, 2021

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 369)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 5, 26Form 4 ↗Insider transaction
  • Oct 5, 26Form 3 ↗Insider transaction
  • Oct 5, 268-K ↗Current report · A senior executive left or was appointed
  • Sep 15, 26SCHEDULE 13G ↗Passive stake · Srinivas Akkaraju · 9.9% · event on Sep 2, 26
  • Sep 2, 268-K ↗Current report · Entered a material agreement
  • Sep 2, 26424B5 ↗Securities offering
  • Aug 31, 26424B3 ↗Securities offering
  • Aug 31, 26424B5 ↗Securities offering
  • Aug 31, 268-K ↗Current report · Other events
  • Aug 14, 2610-Q ↗Quarterly report
  • Aug 14, 268-K ↗Current report · Results
  • Jul 28, 26SCHEDULE 13G/A ↗Passive stake · Sio Capital Management, LLC · 4.9% · event on Jun 30, 26 · amendment
  • Jul 10, 26SCHEDULE 13G/A ↗Passive stake · ArrowMark Colorado Holdings, LLC · 3.7% · event on Jun 30, 26 · amendment
  • Insider transaction · 4 Form 4 filingsshow all 4hide
  • Jun 5, 268-K ↗Current report · Shareholder vote results
  • Jun 5, 26Form 4 ↗Insider transaction
  • May 15, 26SCHEDULE 13G/A ↗Passive stake · Euclidean Capital LLC · 4.9% · event on Mar 31, 26 · amendment
  • May 12, 2610-Q ↗Quarterly report
  • May 12, 268-K ↗Current report · Results
  • May 4, 26SCHEDULE 13G/A ↗Passive stake · Sio Capital Management, LLC · 5.8% · event on Mar 31, 26 · amendment
  • Apr 22, 26DEFA14A ↗Shareholder meeting and votes
  • Apr 22, 26DEF 14A ↗Shareholder meeting and votes

369 filings on record, the oldest from Jul 23, 20.

Listing the 25 most recent filings of the 369 on record.

8-Ks, explained

Stress1Structure3Governance5
  • Oct 5, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Sep 2, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Aug 8, 24StructureA material agreement was terminated+2 more in the same filing8-K 1.02 ↗
  • Jan 18, 24StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
  • Governance3 senior executive changes2022 – 2024show all 3hide
    • Jan 5, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Nov 4, 22GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Jan 6, 22GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Oct 5, 21StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Apr 6, 21GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • ORBIMED ADVISORS LLC9.4%Oct 23, 25SCHEDULE 13D/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Srinivas Akkaraju9.9%Sep 2, 26SCHEDULE 13G ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
  • BML Investment Partners, L.P.9.9%Dec 31, 25SCHEDULE 13G/A ↗1 earlier filing
  • TANG CAPITAL MANAGEMENT, LLC8.9%Sep 16, 25SCHEDULE 13G ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
  • PFM Health Sciences, LP6.4%Mar 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Sio Capital Management, LLC4.9%Jun 30, 26SCHEDULE 13G/A ↗4 earlier filings
show 2 more holdershide
  • Euclidean Capital LLC4.9%Mar 31, 26SCHEDULE 13G/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum.
  • ArrowMark Colorado Holdings, LLC3.7%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Oct 23, 25Sell$1.5MORBIMED ADVISORS LLC↗
  • Sep 10, 25Sell$900KORBIMED ADVISORS LLC↗
  • Jul 1, 25Sell$62KDavid Henry MackPresident and CEO↗
  • Jul 1, 25Sell$30KMichael CarulliChief Financial Officer↗
  • Jul 1, 25Sell$35KDeepika JalotaChief Development Officer↗
  • Jul 1, 25Sell$25KRobert TicktinGeneral Counsel & COO↗
  • Sep 11, 24Sell$4KMichael CarulliChief Financial Officer↗
  • Sep 11, 24Sell$11KDeepika JalotaChief Development Officer↗
  • Nov 22, 23Sell$196KORBIMED ADVISORS LLC↗
  • Sep 15, 23Sell$42KLeila AllandChief Medical Officer↗
  • Sep 15, 23Sell$27KDeepika JalotaChief Development Officer↗
Stock compensation, tax and giftsshow the 11 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Oct 27, 25Compensation$302KDavid Henry MackPresident and CEO↗
  • Jan 3, 25Compensation$9KDavid Henry MackPresident and CEO↗
  • Dec 3, 24Compensation$49KDavid Henry MackPresident and CEO↗
  • Jan 18, 24Compensationamount n/aDavid Henry MackPresident and CEO↗
  • Jan 18, 24Compensationamount n/aMichael CarulliChief Financial Officer↗
  • Jan 18, 24Compensationamount n/aDeepika JalotaChief Development Officer↗
  • Nov 10, 23Giftamount n/aDavid Henry MackPresident and CEO↗
  • Nov 10, 23Giftamount n/aDavid Henry MackPresident and CEO↗
  • Oct 18, 23Compensation$105KDavid Henry MackPresident and CEO↗
  • Aug 7, 23Compensation$45KDavid Henry MackPresident and CEO↗
  • Nov 25, 22Giftamount n/aWinston KungCOO, CFO↗

The full record holds 22 transactions and goes back to Nov 25, 22.

Its sector and its market

PMV Pharmaceuticals, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From PMV Pharmaceuticals, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow PMV Pharmaceuticals, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
369 documents on file, from Jul 23, 2020 to Oct 5, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.